About Us

FSD Pharma, Inc. is a publicly traded holding company, since May 2018.

FSD Pharma was founded by Thomas Fairfull, Zeeshan Saeed and Anthony Durkacz. The first initial of the last names of each of the founders represent the letters FSD.

FSD BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, FSD201 ultra-micronized palmitoylethanolamide (PEA). Ultra-Micro PEA stabilizes mast cells and down-regulates the pro-inflammatory cytokines to effectuate an anti-inflammatory response; it is also known to target the CB2 receptors of the endocannabinoid system of the human body.

FSD Pharma is actively looking to add suitable candidates to its family of compounds and molecules, which are in various stages of FDA (Food & Drug Administration USA) or HC (Health Canada) approved clinical trials, focused in targeting the receptors of the endocannabinoid system and or in the field of legal therapeutic psychedelics. FSD intends to do this by acquiring or investing in other companies which are in these fields and are in line with FSD’s strategic vision.

The Company has successfully completed Phase 1 first-in-human safety and tolerability study for FSD201 and has found the compound to be safe with no serious adverse side effects. This study also validated considerable scientific literature already published in the European Union that claims safety and tolerability of micro-PEA. Ultra-micro PEA is currently being dispensed in Italy and Spain as a prescription based medical food supplement since 2004.

The Company received approval for an Investigational New Drug Application (IND) from the Food and Drug Administration (FDA) for the use of FSD201 to treat COVID-19, the disease caused by the SARS-CoV-2 virus. A randomized, controlled, double-blind, multicenter Phase 2 clinical study is currently underway and is expected to cover 352 hospitalized COVID 19 patients.

Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. The Company is focused on developing FSD201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.